The BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote communication between the pharmaceutical and investment industries, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of the pharmaceutical industry, the CBIIC focuses on China’s latest policies in the pharmaceutical industry, explores the new trends of global pharmaceutical R&D, and hot issues in the investment and financing circle. The CBIIC is built as an authoritative, comprehensive, professional, and international high-level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises, and investors to discuss current trends of innovation and new strategies for investment and cooperation.

Established by PhIRDA, the CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX), Chinese Hospital Association (CHA), Research and Development International (RDI), and iMeta Health Information Consulting Co., Ltd. (iMeta) from 2016 to 2023. Up to now, the CBIIC has attracted over 30,000 participants, 8,000 domestic and foreign pharmaceutical enterprises, and financial and investment institutions. About 900 innovative projects at home and abroad have made roadshows. The One-on-One Partnering System received over 30,000 meeting requests and completed over 3,000 business meetings. The CBIIC has promoted effective communication and precise cooperation between domestic and international pharmaceutical innovation and investment communities, receiving extensive attention at home and abroad, and was praised as the “most popular cooperation platform for pharmaceutical innovation and investment in the Asia-Pacific region”.

Under the new international circumstances, the integration and innovation of the pharmaceutical industry and capital are crucial for stimulating the innovative vitality of original technology of pharmaceutical innovation in China, creating a high-quality ecosystem for pharmaceutical innovation. To discuss the new future of integration and innovation between pharmaceutical industry and capital, the 2024 CBIIC is scheduled to be held in Guangzhou from November 30 to December 1, 2024.

I. Customized Setting and Innovation, Various Sessions to Meet Diverse Needs

The 2024 CBIIC will further open financing channels for pharmaceutical innovation, focus on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle, share opinions on China’s latest pharmaceutical industry policies and the trend of global pharmaceutical innovation. The 2024 CBIIC will set up almost 20 fascinating and excellent parallel sessions including Investment and M&A Forum, Clinical Trial Data Release, and roadshows for Listed Company and Non-Listed Company. Based on China’s development with a global vision, the 2024 CBIIC will also set up the International Projects Roadshow and New Drugs R&D Internationalization Forum. In collaboration with Peking Union Medical College Hospital (PUMCH), the 2024 CBIIC will set up the Clinical Research and Innovation Cooperation Forum, highlighting the latest technological innovations in clinical practice. For the first time, the CBIIC will be held in the Greater Bay Area, with special invitations extended to Hong Kong’s innovative projects for roadshows. Focusing on recent hot topics, the 2024 CBIIC will host seminars to expand the scope of capital engagement in innovation, build a high-level dialogue platform for more innovative projects to seek investment and partners, enhance the core innovation capacity of China’s pharmaceutical industry, and drive domestic innovation to the global market.

II. Great Supports from Global Authoritative Institutions & In-depth Discussion of Better Future with Leading Experts

Prominent experts and distinguished participants have been presented in the CBIIC. Senior officials from relevant departments, as well as domestic and international academicians and experts, including He Wei, Vice Chairman of the Standing Committee of the 14th National People’s Congress (NPC) and chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party (CPWDP); Bi Jingquan, member of Standing Committee of the 14th National Committee of the Chinese People’s Political Consultative Conference (CPPCC), Vice Chairman of the Committee on Economic Affairs of the CPPCC National Committee, and Chairman of China Center for International Economic Exchanges (CCIEE); Chen Deming, former minister of Commerce, and president of the China Association of Enterprise with Foreign Investment (CAEFI); Shang Fulin, Member of Standing Committee and of the 13th CPPCC National Committee, chairman of the Committee on Economic Affairs of the CPPCC National Committee, and former Chairman of the China Banking Regulatory Commission (CBRC); Xu Jinghe, Deputy Commissioner of National Medical Products Administration (NMPA); Zhou Siyuan, Director of the Center for Drug Evaluation (CDE) of the NMPA and Secretary of the Party Committee; Sun Lei, Director of Center for Medical Device Evaluation (CMDE) of NMPA; Liu Pei, former Director of the Department of Policies and Regulations of NMPA; Chen Kaixian, Academician of Chinese Academy of Sciences (CAS); Ding Jian, and Jiang Jiandong, Academicians of Chinese Academy of Engineering (CAE), delivered insightful speeches, providing authoritative policy interpretations and the latest industry trends.

→Click to see Previous Speakers

The 2024 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in the pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China’s capability on transformation and innovation in the pharmaceutical industry.

Since its establishment, the CBIIC has received great support from prestigious institutions in China and around the world, including the Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authoritative academic institutions; embassies and consulates of Canada, the Netherlands, Australia, the Kingdom of Denmark, Singapore and other countries in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan has supported the CBIIC as the exclusive international financial institution sponsor for several times.

III. One-on-One Partnering System Provides Close Communication between Projects and Investors

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors and bridge the investment and financing, the 2024 CBIIC will continue to offer a better and more diverse platform for project presentation and communication. The One-on-One Partnering System will be provided for participants. Investors and roadshow speakers could propose an invitation in this system easily and efficiently. All-round service of face-to-face and online communication and negotiation will be available for participants to seek potential opportunities and commercial values for further collaboration.

IV. Great Attention from Domestic and Global Media and Witness the Integration of Innovation and Investment

Since 2016, the CBIIC was supported by over ten well-known magazines and traditional media at home and abroad, including top leading international academic journal Nature, people.cn, JKB.com.cn, China Pharmaceutical News, IFNEWS.com, Medicine Economic Reporter, and attracted new media and healthcare financial media including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time reports of the event and witness the integration of innovation and investment.

Under the great support of all parties, the CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circles, present pharmaceutical innovative achievements at home and abroad, and lead new investment trends. As the most influential annual grand conference in the Asia-Pacific region, the CBIIC will continue to play a leading role in the development of social capital and pharmaceutical innovation, create a more scientific and attractive investment environment, and contribute to China’s economic and social development to meet the clinical needs and advance the pursuit of Healthy China.